In light of this, future studies using in vivo knockout models will be able to establish in detail the activity of AC on the NF-κB/Nrf-2 pathway and in particular on Nrf-2 in the context of PD, thus evaluating its possible use as a therapeutic agent. Here, NFKB1 is linked to Parkinson disease.